SEC Comment Letter 0000000000-24-008069 to KalVista Pharmaceuticals, Inc. (KALV) (CIK 0001348911) (KALV)
KalVista Pharmaceuticals, Inc. (KALV) (CIK 0001348911)
Date: July 16, 2024 · CIK: 0001348911 · Accession: 0000000000-24-008069
AI Filing Summary & Sentiment
File numbers found in text: 333-280759
Letter
July 16, 2024 Benjamin Palleiko Chief Executive Officer KalVista Pharmaceuticals, Inc. 55 Cambridge Parkway Suite 901E Cambridge, Massachusetts 02142 Re:KalVista Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed July 11, 2024 File No. 333-280759 Dear Benjamin Palleiko: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Julia Forbess
Show Raw Text
July 16, 2024
Benjamin Palleiko
Chief Executive Officer
KalVista Pharmaceuticals, Inc.
55 Cambridge Parkway
Suite 901E
Cambridge, Massachusetts 02142
Re:KalVista Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed July 11, 2024
File No. 333-280759
Dear Benjamin Palleiko:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Julia Forbess